{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:20:18Z","timestamp":1788405618914,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,8,21]],"date-time":"2014-08-21T00:00:00Z","timestamp":1408579200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s40262-014-0166-x","type":"journal-article","created":{"date-parts":[[2014,8,20]],"date-time":"2014-08-20T05:09:37Z","timestamp":1408511377000},"page":"931-941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers"],"prefix":"10.1007","volume":"53","author":[{"given":"Margreke J. E.","family":"Brill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"van Rongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aletta P. I.","family":"Houwink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus","family":"Burggraaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"van Ramshorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 J.","family":"Wiezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P. A.","family":"van Dongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherijne A. J.","family":"Knibbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,21]]},"reference":[{"issue":"6","key":"166_CR1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ijo.2012.159","volume":"37","author":"R Sturm","year":"2013","unstructured":"Sturm R, Hattori A. Morbid obesity rates continue to rise rapidly in the United States. Int J Obes (Lond). 2013;37(6):889\u201391. doi: 10.1038\/ijo.2012.159 .","journal-title":"Int J Obes (Lond)"},{"key":"166_CR2","unstructured":"Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of Obesity in the United Stated, 2009\u20132010. NCHS Data Brief 2012. http:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db82.pdf . Accessed 11 Aug 2014."},{"key":"166_CR3","unstructured":"World Obesity Federation. 2014. Registered in England and Wales, 3802726. http:\/\/www.worldobesity.org\/aboutobesity\/world-map-obesity\/ . Accessed 15 Aug 2014."},{"issue":"6","key":"166_CR4","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s11095-006-0071-6","volume":"23","author":"K Yoshinari","year":"2006","unstructured":"Yoshinari K, Takagi S, Yoshimasa T, Sugatani J, Miwa M. Hepatic CYP3A expression is attenuated in obese mice fed a high-fat diet. Pharm Res. 2006;23(6):1188\u2013200. doi: 10.1007\/s11095-006-0071-6 .","journal-title":"Pharm Res"},{"issue":"1\u20132","key":"166_CR5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lfs.2011.05.005","volume":"89","author":"R Ghose","year":"2011","unstructured":"Ghose R, Omoluabi O, Gandhi A, Shah P, Strohacker K, Carpenter KC, et al. Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sci. 2011;89(1\u20132):57\u201364. doi: 10.1016\/j.lfs.2011.05.005 .","journal-title":"Life Sci"},{"issue":"10","key":"166_CR6","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","volume":"37","author":"CD Fisher","year":"2009","unstructured":"Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos. 2009;37(10):2087\u201394. doi: 10.1124\/dmd.109.027466 .","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"166_CR7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.cgh.2006.12.021","volume":"5","author":"D Kolwankar","year":"2007","unstructured":"Kolwankar D, Vuppalanchi R, Ethell B, Jones DR, Wrighton SA, Hall SD, et al. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol. 2007;5(3):388\u201393. doi: 10.1016\/j.cgh.2006.12.021 .","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1\u20132","key":"166_CR8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000318741","volume":"83","author":"A Wree","year":"2011","unstructured":"Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver\u2014the link between adipocytes and hepatocytes. Digestion. 2011;83(1\u20132):124\u201333. doi: 10.1159\/000318741 .","journal-title":"Digestion"},{"issue":"4","key":"166_CR9","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1381\/096089203322190853","volume":"13","author":"M Moretto","year":"2003","unstructured":"Moretto M, Kupski C, Mottin CC, Repetto G, Garcia Toneto M, Rizzolli J, et al. Hepatic steatosis in patients undergoing bariatric surgery and its relationship to body mass index and co-morbidities. Obes Surg. 2003;13(4):622\u20134.","journal-title":"Obes Surg"},{"issue":"1","key":"166_CR10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103\u201341. doi: 10.1016\/j.pharmthera.2012.12.007 .","journal-title":"Pharmacol Ther"},{"key":"166_CR11","unstructured":"Flockhart A. Cytochrome P450 drug interaction table. Indiana University School of Medicine. http:\/\/medicine.iupui.edu\/clinpharm\/ddis\/clinical-table\/ . Accessed 29 Apr 2014."},{"issue":"3","key":"166_CR12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/clpt.2012.261","volume":"93","author":"M Ulvestad","year":"2013","unstructured":"Ulvestad M, Skottheim IB, Jakobsen GS, Bremer S, Molden E, Asberg A, et al. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. Clin Pharmacol Ther. 2013;93(3):275\u201382. doi: 10.1038\/clpt.2012.261 .","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"166_CR13","first-page":"8","volume":"37","author":"M Kotlyar","year":"1999","unstructured":"Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther. 1999;37(1):8\u201319.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"166_CR14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","volume":"51","author":"MJ Brill","year":"2012","unstructured":"Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51(5):277\u2013304. doi: 10.2165\/11599410-000000000-00000 .","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"166_CR15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00000542-198461010-00006","volume":"61","author":"DJ Greenblatt","year":"1984","unstructured":"Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984;61(1):27\u201335.","journal-title":"Anesthesiology"},{"issue":"5","key":"166_CR16","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI200525102","volume":"115","author":"KE Wellen","year":"2005","unstructured":"Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115(5):1111\u20139. doi: 10.1172\/JCI25102 .","journal-title":"J Clin Invest"},{"issue":"5","key":"166_CR17","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaci.2005.02.023","volume":"115","author":"G Fantuzzi","year":"2005","unstructured":"Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115(5):911\u20139. doi: 10.1016\/j.jaci.2005.02.023 quiz 20.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"166_CR18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/clpt.2009.311","volume":"87","author":"P Mathieu","year":"2010","unstructured":"Mathieu P, Lemieux I, Despres JP. Obesity, inflammation, and cardiovascular risk. Clin Pharmacol Ther. 2010;87(4):407\u201316. doi: 10.1038\/clpt.2009.311 .","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"166_CR19","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1096\/fj.02-0195fje","volume":"16","author":"R Jover","year":"2002","unstructured":"Jover R, Bort R, Gomez-Lechon MJ, Castell JV. Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J. 2002;16(13):1799\u2013801. doi: 10.1096\/fj.02-0195fje .","journal-title":"FASEB J"},{"key":"166_CR20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev.pharmtox.46.120604.141059","volume":"46","author":"AE Aitken","year":"2006","unstructured":"Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol. 2006;46:123\u201349. doi: 10.1146\/annurev.pharmtox.46.120604.141059 .","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"166_CR21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2174\/1389200043335559","volume":"5","author":"KW Renton","year":"2004","unstructured":"Renton KW. Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab. 2004;5(3):235\u201343.","journal-title":"Curr Drug Metab"},{"issue":"24","key":"166_CR22","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1158\/1078-0432.CCR-06-0023","volume":"12","author":"KA Charles","year":"2006","unstructured":"Charles KA, Rivory LP, Brown SL, Liddle C, Clarke SJ, Robertson GR. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin Cancer Res. 2006;12(24):7492\u20137. doi: 10.1158\/1078-0432.CCR-06-0023 .","journal-title":"Clin Cancer Res"},{"issue":"3","key":"166_CR23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.toxlet.2010.06.003","volume":"197","author":"J Yang","year":"2010","unstructured":"Yang J, Hao C, Yang D, Shi D, Song X, Luan X, et al. Pregnane X receptor is required for interleukin-6-mediated down-regulation of cytochrome P450 3A4 in human hepatocytes. Toxicol Lett. 2010;197(3):219\u201326. doi: 10.1016\/j.toxlet.2010.06.003 .","journal-title":"Toxicol Lett"},{"key":"166_CR24","author":"NJ Vet","year":"2010","unstructured":"Vet NJ, de Hoog M, Tibboel D, de Wildt SN. The effect of critical illness and inflammation on midazolam therapy in children. Pediatr Crit Care Med. 2010. doi: 10.1097\/PCC.0b013e3181fe406d .","journal-title":"Pediatr Crit Care Med"},{"issue":"6","key":"166_CR25","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2044.1987.tb03086.x","volume":"42","author":"MP Shelly","year":"1987","unstructured":"Shelly MP, Mendel L, Park GR. Failure of critically ill patients to metabolise midazolam. Anaesthesia. 1987;42(6):619\u201326.","journal-title":"Anaesthesia"},{"issue":"3","key":"166_CR26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00008571-200004000-00001","volume":"10","author":"DS Streetman","year":"2000","unstructured":"Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000;10(3):187\u2013216.","journal-title":"Pharmacogenetics"},{"issue":"6","key":"166_CR27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1365-2362.2003.01154.x","volume":"33","author":"M Lindell","year":"2003","unstructured":"Lindell M, Karlsson MO, Lennernas H, Pahlman L, Lang MA. Variable expression of CYP and Pgp genes in the human small intestine. Eur J Clin Invest. 2003;33(6):493\u20139.","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"166_CR28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-2125.2005.02389.x","volume":"60","author":"M Thorn","year":"2005","unstructured":"Thorn M, Finnstrom N, Lundgren S, Rane A, Loof L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol. 2005;60(1):54\u201360. doi: 10.1111\/j.1365-2125.2005.02389.x .","journal-title":"Br J Clin Pharmacol"},{"key":"166_CR29","volume-title":"NONMEM user\u2019s guides (1989\u20132006)","author":"S Beal","year":"2006","unstructured":"Beal S, Sheiner LB, Boeckmann A. NONMEM user\u2019s guides (1989\u20132006). Ellicott City: Icon Development Solutions; 2006."},{"key":"166_CR30","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1007\/s11095-006-9067-5","volume":"23","author":"K Brendel","year":"2006","unstructured":"Brendel K, Comets E, Laffont CM, Laveille C, Mentr\u00e9 F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23:2036\u201349.","journal-title":"Pharm Res"},{"issue":"5","key":"166_CR31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","volume":"34","author":"RM Savic","year":"2007","unstructured":"Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34(5):711\u201326. doi: 10.1007\/s10928-007-9066-0 .","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"166_CR32","volume-title":"Pharmacokinetic-pharmacodynamic modeling and simulation","author":"P Bonate","year":"2006","unstructured":"Bonate P. Pharmacokinetic-pharmacodynamic modeling and simulation. New York: Springer; 2006."},{"issue":"10","key":"166_CR33","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","volume":"44","author":"S Janmahasatian","year":"2005","unstructured":"Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051\u201365.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"166_CR34","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1381\/096089206777346682","volume":"16","author":"MC Lewis","year":"2006","unstructured":"Lewis MC, Phillips ML, Slavotinek JP, Kow L, Thompson CH, Toouli J. Change in liver size and fat content after treatment with Optifast very low calorie diet. Obes Surg. 2006;16(6):697\u2013701. doi: 10.1381\/096089206777346682 .","journal-title":"Obes Surg"},{"issue":"2","key":"166_CR35","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-198409020-00005","volume":"9","author":"DR Abernethy","year":"1984","unstructured":"Abernethy DR, Greenblatt DJ, Divoll M, Smith RB, Shader RI. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clin Pharmacokinet. 1984;9(2):177\u201383.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"166_CR36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1208\/s12248-010-9212-2","volume":"12","author":"XS Li","year":"2010","unstructured":"Li XS, Nielsen J, Cirincione B, Li H, Addy C, Wagner J, et al. Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist. AAPS J. 2010;12(4):537\u201347. doi: 10.1208\/s12248-010-9212-2 .","journal-title":"AAPS J"},{"issue":"5","key":"166_CR37","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/clpt.1992.54","volume":"51","author":"Y Caraco","year":"1992","unstructured":"Caraco Y, Zylber-Katz E, Berry EM, Levy M. Significant weight reduction in obese subjects enhances carbamazepine elimination. Clin Pharmacol Ther. 1992;51(5):501\u20136.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"166_CR38","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","volume":"8","author":"J Yang","year":"2007","unstructured":"Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab. 2007;8(7):676\u201384.","journal-title":"Curr Drug Metab"},{"issue":"6","key":"166_CR39","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1053\/jhep.2002.33215","volume":"35","author":"A Rostami-Hodjegan","year":"2002","unstructured":"Rostami-Hodjegan A, Tucker GT. The effects of portal shunts on intestinal cytochrome P450 3A activity. Hepatology. 2002;35(6):1549\u201350. doi: 10.1053\/jhep.2002.33215 ; author reply 50\u20131.","journal-title":"Hepatology"},{"issue":"5","key":"166_CR40","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.clnu.2012.02.009","volume":"31","author":"TF Teixeira","year":"2012","unstructured":"Teixeira TF, Souza NC, Chiarello PG, Franceschini SC, Bressan J, Ferreira CL, et al. Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors. Clin Nutr. 2012;31(5):735\u201340. doi: 10.1016\/j.clnu.2012.02.009 .","journal-title":"Clin Nutr"},{"key":"166_CR41","author":"F Horton","year":"2013","unstructured":"Horton F, Wright J, Smith L, Hinton PJ, Robertson MD. Increased intestinal permeability to oral chromium (Cr)\u2014EDTA in human Type 2 diabetes. Diabet Med. 2013. doi: 10.1111\/dme.12360 .","journal-title":"Diabet Med"},{"issue":"2","key":"166_CR42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","volume":"11","author":"M Jamei","year":"2009","unstructured":"Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 2009;11(2):225\u201337. doi: 10.1208\/s12248-009-9099-y .","journal-title":"AAPS J"},{"issue":"4","key":"166_CR43","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF00562804","volume":"19","author":"MT Smith","year":"1981","unstructured":"Smith MT, Eadie MJ, Brophy TO. The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol. 1981;19(4):271\u20138.","journal-title":"Eur J Clin Pharmacol"},{"key":"166_CR44","unstructured":"Alexander JK, Dennis EW, Smith WG, Amad KH, Duncan WC, Austin RC. Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. Cardiovasc Res Cent Bull. 1962;1:39\u201344."},{"issue":"5","key":"166_CR45","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/0002-9343(83)91071-9","volume":"74","author":"FH Messerli","year":"1983","unstructured":"Messerli FH, Sundgaard-Riise K, Reisin E, Dreslinski G, Dunn FG, Frohlich E. Disparate cardiovascular effects of obesity and arterial hypertension. Am J Med. 1983;74(5):808\u201312.","journal-title":"Am J Med"},{"issue":"8\u20139","key":"166_CR46","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/j.1552-4604.1983.tb02750.x","volume":"23","author":"DR Abernethy","year":"1983","unstructured":"Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Prolonged accumulation of diazepam in obesity. J Clin Pharmacol. 1983;23(8\u20139):369\u201376.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"166_CR47","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1023\/A:1015939917646","volume":"6","author":"MO Karlsson","year":"1989","unstructured":"Karlsson MO, Bredberg U. Estimation of bioavailability on a single occasion after semisimultaneous drug administration. Pharm Res. 1989;6(9):817\u201321.","journal-title":"Pharm Res."},{"issue":"2","key":"166_CR48","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF01063554","volume":"18","author":"MO Karlsson","year":"1990","unstructured":"Karlsson MO, Bredberg U. Bioavailability estimation by semisimultaneous drug administration: a Monte Carlo simulation study. J Pharmacokinet Biopharm. 1990;18(2):103\u201320.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"3","key":"166_CR49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1992.136","volume":"52","author":"U Bredberg","year":"1992","unstructured":"Bredberg U, Karlsson MO, Borgstrom L. A comparison between the semisimultaneous and the stable isotope techniques for bioavailability estimation of terbutaline in humans. Clin Pharmacol Ther. 1992;52(3):239\u201348.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"166_CR50","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1067\/mcp.2002.129068","volume":"72","author":"JI Lee","year":"2002","unstructured":"Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther. 2002;72(6):718\u201328. doi: 10.1067\/mcp.2002.129068 .","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-014-0166-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0166-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0166-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:15:01Z","timestamp":1565741701000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-014-0166-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,21]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["166"],"URL":"https:\/\/doi.org\/10.1007\/s40262-014-0166-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,21]]}}}